FR2838124B1 - Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique - Google Patents

Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique

Info

Publication number
FR2838124B1
FR2838124B1 FR0204158A FR0204158A FR2838124B1 FR 2838124 B1 FR2838124 B1 FR 2838124B1 FR 0204158 A FR0204158 A FR 0204158A FR 0204158 A FR0204158 A FR 0204158A FR 2838124 B1 FR2838124 B1 FR 2838124B1
Authority
FR
France
Prior art keywords
sub
pyridazino
indole
dihydro
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0204158A
Other languages
English (en)
French (fr)
Other versions
FR2838124A1 (fr
Inventor
Jacques Froissant
Benoit Marabout
Frank Marguet
Frederic Puech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to FR0204158A priority Critical patent/FR2838124B1/fr
Priority to UA20041008012A priority patent/UA77273C2/uk
Priority to PT03730299T priority patent/PT1492792E/pt
Priority to MEP-237/08A priority patent/MEP23708A/xx
Priority to HK05108771.3A priority patent/HK1074632B/xx
Priority to KR1020047015629A priority patent/KR100975999B1/ko
Priority to JP2003580339A priority patent/JP4575670B2/ja
Priority to DE60304327T priority patent/DE60304327T2/de
Priority to PCT/FR2003/001027 priority patent/WO2003082874A2/fr
Priority to AT03730299T priority patent/ATE321763T1/de
Priority to CNB038122227A priority patent/CN100406459C/zh
Priority to EP03730299A priority patent/EP1492792B1/fr
Priority to NZ535741A priority patent/NZ535741A/en
Priority to AU2003240930A priority patent/AU2003240930B2/en
Priority to DK03730299T priority patent/DK1492792T3/da
Priority to MXPA04009635A priority patent/MXPA04009635A/es
Priority to CNB2006101003182A priority patent/CN100543016C/zh
Priority to US10/509,695 priority patent/US7235554B2/en
Priority to IL16425703A priority patent/IL164257A0/xx
Priority to ES03730299T priority patent/ES2261940T3/es
Priority to HRP20040911 priority patent/HRP20040911B1/xx
Priority to YUP-869/04A priority patent/RS51244B/sr
Priority to CA2481460A priority patent/CA2481460C/en
Priority to EA200401146A priority patent/EA007219B1/ru
Priority to SI200330306T priority patent/SI1492792T1/sl
Priority to PL03372617A priority patent/PL372617A1/xx
Priority to MEP-2008-237A priority patent/ME00081B/me
Priority to BR0309018-3A priority patent/BR0309018A/pt
Publication of FR2838124A1 publication Critical patent/FR2838124A1/fr
Application granted granted Critical
Publication of FR2838124B1 publication Critical patent/FR2838124B1/fr
Priority to IL164257A priority patent/IL164257A/en
Priority to IS7478A priority patent/IS2483B/is
Priority to NO20044153A priority patent/NO329426B1/no
Priority to ZA2004/07945A priority patent/ZA200407945B/en
Priority to HK07108859.6A priority patent/HK1102371B/xx
Priority to CY20061100885T priority patent/CY1104998T1/el
Priority to US11/749,342 priority patent/US7323467B2/en
Priority to US11/867,366 priority patent/US7405306B2/en
Priority to US12/143,059 priority patent/US20080255129A1/en
Priority to JP2010141683A priority patent/JP5277208B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
FR0204158A 2002-04-03 2002-04-03 Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique Expired - Fee Related FR2838124B1 (fr)

Priority Applications (38)

Application Number Priority Date Filing Date Title
FR0204158A FR2838124B1 (fr) 2002-04-03 2002-04-03 Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
UA20041008012A UA77273C2 (en) 2002-04-03 2003-02-04 3-heteroaryl-3,5-dihydro-4oxo-4h-pyridazino[4,5-?]indol-1-acetamide derivatives, their production and therapeutic use
CA2481460A CA2481460C (en) 2002-04-03 2003-04-02 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics
HK05108771.3A HK1074632B (en) 2002-04-03 2003-04-02 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
KR1020047015629A KR100975999B1 (ko) 2002-04-03 2003-04-02 3-헤테로아릴-3,5-디히드로-4-옥소-4H-피리다지노[4,5-b]인돌-1-아세트아미드 유도체, 그의 제조 방법 및의약에서의 그의 용도
JP2003580339A JP4575670B2 (ja) 2002-04-03 2003-04-02 3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用
DE60304327T DE60304327T2 (de) 2002-04-03 2003-04-02 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINOi4,5-BöINDOLACETAMIDDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE THERAPEUTISCHE VERWENDUNG
PCT/FR2003/001027 WO2003082874A2 (fr) 2002-04-03 2003-04-02 DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
AT03730299T ATE321763T1 (de) 2002-04-03 2003-04-02 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino¬4, - bäindolacetamidderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
CNB038122227A CN100406459C (zh) 2002-04-03 2003-04-02 3-杂芳基-3,5-二氢-4-氧代-4H-哒嗪并[4,5-b]吲哚-1-乙酰胺衍生物,其制备和在治疗中的应用
EP03730299A EP1492792B1 (fr) 2002-04-03 2003-04-02 Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino¬4,5-b|indole-1-acetamide,leur preparation et leur application en therapeutique
NZ535741A NZ535741A (en) 2002-04-03 2003-04-02 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
AU2003240930A AU2003240930B2 (en) 2002-04-03 2003-04-02 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
DK03730299T DK1492792T3 (da) 2002-04-03 2003-04-02 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indol-1-acetamidderivater, deres fremstilling og deres terapeutiske anvendelse
MXPA04009635A MXPA04009635A (es) 2002-04-03 2003-04-02 Derivados 3-heteroaril -3, 5-dihidro-4 -oxo-4h -piridacino [4, 5-b] indola-1 -acetamida, preparacion y uso de los mismos en medicamentos.
CNB2006101003182A CN100543016C (zh) 2002-04-03 2003-04-02 3-杂芳基-3,5-二氢-4-氧代-4H-哒嗪并[4,5-b]吲哚-1-乙酰胺衍生物的中间体化合物
US10/509,695 US7235554B2 (en) 2002-04-03 2003-04-02 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments
IL16425703A IL164257A0 (en) 2002-04-03 2003-04-02 3-Heteroaryl-3,5-dihydro-4-oxo-4h-pyridazinoÄ4,5-bÜindole-1-acetamide derivatives, preparation and use thereof in medicaments
ES03730299T ES2261940T3 (es) 2002-04-03 2003-04-02 Derivados de 3-hetoeroaril-3,5-dihidro-4-oxo-4hpiridazino-(4,5-b)-indol-1-acetamida, su preparacion y su aplicacion en terapeutica.
HRP20040911 HRP20040911B1 (en) 2002-04-03 2003-04-02 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
PT03730299T PT1492792E (pt) 2002-04-03 2003-04-02 Derivados de 3-heteroaril-3,5-di-hidro-4-oxo-4h-piridazino(4, 5-b) ao em terapeutica.
SI200330306T SI1492792T1 (sl) 2002-04-03 2003-04-02 Derivati 3-heteroaril-3,5-dihidro-4-okso-4H-piridazino(4,5-b)indol-1-acetamida, njihova priprava innjihova terapevtska uporaba
MEP-237/08A MEP23708A (en) 2002-04-03 2003-04-02 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
EA200401146A EA007219B1 (ru) 2002-04-03 2003-04-02 ПРОИЗВОДНЫЕ 3-ГЕТЕРОАРИЛ-3,5-ДИГИДРО-4-ОКСО-4Н-ПИРИДАЗИНО[4,5-b]ИНДОЛ-1-АЦЕТАМИДА, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВ
PL03372617A PL372617A1 (en) 2002-04-03 2003-04-02 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino 4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
MEP-2008-237A ME00081B (me) 2002-04-03 2003-04-02 Derivati 3-heteroaril-3,5-dihidro-4-okso-4h-piridazino (4,5-b)- indol-1-acetamida, njihovo dobijanje i primjena u terapiji
BR0309018-3A BR0309018A (pt) 2002-04-03 2003-04-02 Derivados de 3-heteroaril-3,5-dihidro-4-oxo-4h-piridazino[4,5-b]ind ol-1-acetamida, sua preparação e sua aplicação em terapêutica
YUP-869/04A RS51244B (sr) 2002-04-03 2003-04-02 Derivati 3-heteroaril-3,5-dihidro-4-okso-4h-piridazino(4,5- b)-indol-1-acetamida, njihovo dobijanje i primena u terapiji
IL164257A IL164257A (en) 2002-04-03 2004-09-23 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1- acetamide derivatives, their preparation and use thereof in medicaments
IS7478A IS2483B (is) 2002-04-03 2004-09-30 3-Heteróarýl-3,5-díhýdró-4-oxó-4H-pýridasínó[4,5-b]indól-1-asetamíð afleiður, framleiðsla og notkunþeirra í lyfjum
NO20044153A NO329426B1 (no) 2002-04-03 2004-09-30 3-heteroaryl-3,5-dihydro-4-okso-4H-pyridazino[4,5-b]indol-1-acetamid-derivater, farmasoytiske preparater omfattende slike, fremgangsmater for fremstilling derav og syntese-mellomprodukter derav
ZA2004/07945A ZA200407945B (en) 2002-04-03 2004-10-01 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives preparation and use thereof in medicaments
HK07108859.6A HK1102371B (en) 2002-04-03 2005-10-04 Intermediate compound of 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives
CY20061100885T CY1104998T1 (el) 2002-04-03 2006-06-29 Εκδοχα 3-ετεροαρυλο-3,5-διϋδρο-4-οξο-4η-πυριδαζινο [4,5-b] ινδολο-1-ακεταμιδιου, η διαδικασια παρασκευης τους kai h εφαρμογη τους στην θεραπευτικη
US11/749,342 US7323467B2 (en) 2002-04-03 2007-05-16 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics
US11/867,366 US7405306B2 (en) 2002-04-03 2007-10-04 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics
US12/143,059 US20080255129A1 (en) 2002-04-03 2008-06-20 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics
JP2010141683A JP5277208B2 (ja) 2002-04-03 2010-06-22 3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0204158A FR2838124B1 (fr) 2002-04-03 2002-04-03 Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2838124A1 FR2838124A1 (fr) 2003-10-10
FR2838124B1 true FR2838124B1 (fr) 2004-05-28

Family

ID=28052083

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0204158A Expired - Fee Related FR2838124B1 (fr) 2002-04-03 2002-04-03 Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique

Country Status (28)

Country Link
US (4) US7235554B2 (cg-RX-API-DMAC10.html)
EP (1) EP1492792B1 (cg-RX-API-DMAC10.html)
JP (2) JP4575670B2 (cg-RX-API-DMAC10.html)
KR (1) KR100975999B1 (cg-RX-API-DMAC10.html)
CN (2) CN100406459C (cg-RX-API-DMAC10.html)
AT (1) ATE321763T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003240930B2 (cg-RX-API-DMAC10.html)
BR (1) BR0309018A (cg-RX-API-DMAC10.html)
CA (1) CA2481460C (cg-RX-API-DMAC10.html)
CY (1) CY1104998T1 (cg-RX-API-DMAC10.html)
DE (1) DE60304327T2 (cg-RX-API-DMAC10.html)
DK (1) DK1492792T3 (cg-RX-API-DMAC10.html)
EA (1) EA007219B1 (cg-RX-API-DMAC10.html)
ES (1) ES2261940T3 (cg-RX-API-DMAC10.html)
FR (1) FR2838124B1 (cg-RX-API-DMAC10.html)
HR (1) HRP20040911B1 (cg-RX-API-DMAC10.html)
IL (2) IL164257A0 (cg-RX-API-DMAC10.html)
IS (1) IS2483B (cg-RX-API-DMAC10.html)
ME (2) MEP23708A (cg-RX-API-DMAC10.html)
MX (1) MXPA04009635A (cg-RX-API-DMAC10.html)
NO (1) NO329426B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ535741A (cg-RX-API-DMAC10.html)
PL (1) PL372617A1 (cg-RX-API-DMAC10.html)
PT (1) PT1492792E (cg-RX-API-DMAC10.html)
RS (1) RS51244B (cg-RX-API-DMAC10.html)
UA (1) UA77273C2 (cg-RX-API-DMAC10.html)
WO (1) WO2003082874A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200407945B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017932A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
JP2009504752A (ja) * 2005-08-19 2009-02-05 シェーリング コーポレイション 治療剤としての縮合三環式mGluR1アンタゴニスト
US20120041211A1 (en) * 2009-01-30 2012-02-16 Sythana Suresh Kumar Novel process for preparing carboxy-containing pyrazoleamido compounds 597
CN105330665B (zh) * 2015-11-04 2017-10-03 衡阳师范学院 一种抑制激肽释放酶klk7的化合物、制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2788776B1 (fr) * 1999-01-26 2001-02-23 Synthelabo Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique
FR2811897A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2811990A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo DERIVES DE 1-(4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1 -CARBONYL)PIPERAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2833953B1 (fr) * 2001-12-21 2004-12-03 Sanofi Synthelabo DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Also Published As

Publication number Publication date
IS7478A (is) 2004-09-30
AU2003240930B2 (en) 2009-07-30
RS51244B (sr) 2010-12-31
KR20040094904A (ko) 2004-11-10
NO329426B1 (no) 2010-10-18
EP1492792B1 (fr) 2006-03-29
US7405306B2 (en) 2008-07-29
US7235554B2 (en) 2007-06-26
JP4575670B2 (ja) 2010-11-04
KR100975999B1 (ko) 2010-08-17
CA2481460A1 (en) 2003-10-09
BR0309018A (pt) 2005-02-01
EP1492792A2 (fr) 2005-01-05
HK1074632A1 (zh) 2005-11-18
ES2261940T3 (es) 2006-11-16
UA77273C2 (en) 2006-11-15
EA007219B1 (ru) 2006-08-25
JP2010248221A (ja) 2010-11-04
NZ535741A (en) 2007-03-30
DE60304327D1 (de) 2006-05-18
WO2003082874A2 (fr) 2003-10-09
JP2005527566A (ja) 2005-09-15
CN1656099A (zh) 2005-08-17
DK1492792T3 (da) 2006-08-14
DE60304327T2 (de) 2006-12-28
JP5277208B2 (ja) 2013-08-28
HK1102371A1 (en) 2007-11-16
US20070219202A1 (en) 2007-09-20
CN100406459C (zh) 2008-07-30
MXPA04009635A (es) 2005-07-13
PT1492792E (pt) 2006-08-31
MEP23708A (en) 2010-06-10
IS2483B (is) 2008-12-15
US7323467B2 (en) 2008-01-29
ZA200407945B (en) 2005-11-30
CN100543016C (zh) 2009-09-23
US20050124615A1 (en) 2005-06-09
CA2481460C (en) 2011-02-15
US20080076775A1 (en) 2008-03-27
CY1104998T1 (el) 2009-11-04
NO20044153L (no) 2004-12-27
HRP20040911A2 (en) 2004-12-31
US20080255129A1 (en) 2008-10-16
HRP20040911B1 (en) 2012-11-30
WO2003082874A3 (fr) 2004-04-01
PL372617A1 (en) 2005-07-25
CN1970538A (zh) 2007-05-30
EA200401146A1 (ru) 2005-06-30
ME00081B (me) 2010-10-10
AU2003240930A1 (en) 2003-10-13
FR2838124A1 (fr) 2003-10-10
ATE321763T1 (de) 2006-04-15
IL164257A (en) 2009-11-18
IL164257A0 (en) 2005-12-18
RS86904A (sr) 2006-12-15

Similar Documents

Publication Publication Date Title
HRP20020712B1 (hr) Farmaceutske strukture koje sadrže derivate azetidina, novi derivati azetidina i njihovo pripremanje
RU2376287C2 (ru) Производные бензамида, способ их получения и их применение, фармацевтическая композиция и способ обеспечения ингибирующего действия по отношению к hdac
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
IL152848A0 (en) 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
UA26401C2 (uk) Заміщеhі 3-аміhохіhуклідиhи
ATE316083T1 (de) Adamantanderivate
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
DE69023321D1 (de) Antipicornaviral-Pyridazinamine.
NZ515407A (en) 4-Phenyl-pyrimidine derivatives
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
YU49902A (sh) Supstituisani derivati piperazina kao mtp inhibitori
CY1106029T1 (el) Παραγωγα 3-ετepοαρυλιο-3,5-διυδρο-4-οξο-4η-πυριδαζινο[4,5-β]ινδολη-1-καρβοξαμιδο, η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη
NO20044153L (no) 3-heteroaryl-3,5-dihydro-4-okso-4H-pyridazino[4,5-b]indol-1-acetamid-derivater, fremstilling og anvendelse derav i medikamenter
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
WO2005095399A3 (fr) Derives pyrrolo (2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
MEP24408A (en) Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, the preparation thereof and the application of same in therapeutics
YU16196A (sh) Upotreba novih benzohinolin-3-ona i njihovih farmaceutski prihvatljivih soli za proizvodnju leka
HK1042288A1 (zh) 6-[[(芳基和雜芳基)氧]甲基]-萘基-2-甲亞胺酸酰胺衍生物,其製備方法及其在治療方面的應用
ATE500241T1 (de) Phenyl- und pyridyl-piperidine mit tnf-wirkung
GR1001123B (el) Μεθοδος παρασκευης 1,4-διυδροπυριδινων.
CO5631444A2 (es) Derivados 3-heteroaril-3,5-dihidro-4-oxo-4h-piridazino [4,5- b] indol-1-ecetamida
UY25942A1 (es) Derivados de 7h-pirrolo (2,3-d)pirimidina, para compuestos intermedios, formulaciones farmacéuticas que los contienen y uso

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20141231